$TECH News

RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

Benchmark Downgrades Bio-Techne to Hold

Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

Merck KGaA to acquire Bio-Techne in $11.3 billion deal

Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout

Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

William Blair Downgrades Bio-Techne to Market Perform

Bio-Techne Corporation (TECH) Merck KGaA - M&A Call - Slideshow

Bio-Techne Corporation (TECH) M&A Call Transcript

Baird Maintains Neutral on Bio-Techne, Raises Price Target to $73

Germany's Merck KGaA Swoops In With $11.3 Billion Medtech Buyout

Why Bio-Techne (TECH) Stock Is Trading Up Today

Bio-Techne (TECH) Stock Valuation After New Refeyn Bispecific Antibody Analysis Collaboration

'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News

Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers

Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now?

Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65

New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)